Pemvidutide vs Tirzepatide

Overview

Pemvidutide (ALT-801) is Altimmune’s investigational dual GLP-1/glucagon receptor agonist, while tirzepatide is Eli Lilly’s approved GLP-1/GIP dual agonist. These compounds represent different dual agonist strategies for obesity.

Key distinction: Different secondary receptors - pemvidutide activates glucagon receptors while tirzepatide activates GIP receptors, leading to potentially different metabolic profiles.

Key Facts

Aspect	Pemvidutide	Tirzepatide
Developer	Altimmune	Eli Lilly
Class	GLP-1/Glucagon dual agonist	GLP-1/GIP dual agonist
FDA Status	Investigational (Phase 2)	Approved
Target Indications	Obesity, NASH	T2D, Obesity

Mechanism Comparison

Aspect	Pemvidutide	Tirzepatide
GLP-1 Receptor	Agonist	Agonist
Second Target	Glucagon receptor (agonist)	GIP receptor (agonist)
Weight loss mechanism	Appetite + energy expenditure	Appetite + insulin/metabolism
Liver effects	Potential direct NASH benefit	Indirect via weight loss

How They Work

Pemvidutide:

• GLP-1 agonism reduces appetite and food intake
• Glucagon agonism increases energy expenditure
• Glucagon may promote hepatic lipid oxidation
• Dual mechanism may preserve lean mass during weight loss
• Potential direct effects on fatty liver disease

Tirzepatide:

• GLP-1 agonism for appetite suppression
• GIP agonism enhances insulin secretion
• Combined effect on glucose metabolism
• Potent weight loss through appetite reduction
• Liver benefits primarily through weight loss

Glucagon vs GIP: Different Approaches

Effect	Glucagon Agonism (Pemvidutide)	GIP Agonism (Tirzepatide)
Blood glucose	Can increase (counterregulated by GLP-1)	Generally neutral/beneficial
Energy expenditure	Increased	Minimal direct effect
Liver fat	May directly reduce	Reduces via weight loss
Lean mass preservation	Potentially better	Standard
Safety concern	Hyperglycemia risk	Well-tolerated

Evidence Quality

Pemvidutide Research

Trial Phase	Status	Key Findings
Phase 1	Completed	Safety established
Phase 2 (MOMENTUM)	Completed	~15.6% weight loss (48 weeks)
Phase 2 (NASH)	Ongoing	Liver-focused endpoints
Phase 3	Not started	Planned

Current evidence:

• Phase 2 showed 15.6% weight loss at 48 weeks
• Improvements in liver enzymes observed
• Fat mass preferentially lost over lean mass (claimed)
• NASH-specific trials underway

Tirzepatide Research

Trial Phase	Status	Key Findings
SURPASS	Completed	T2D efficacy established
SURMOUNT	Completed	Up to 22% weight loss
SYNERGY-NASH	Ongoing	NASH indication
Post-marketing	Active	Real-world data

Established evidence:

• Robust Phase 3 data in T2D and obesity
• 20-22% weight loss in obesity trials
• NASH trials ongoing (not yet approved for this)
• Extensive safety database

Efficacy Comparison

Weight Loss

Metric	Pemvidutide	Tirzepatide
Trial duration	48 weeks	72 weeks
Weight loss	~15.6%	~22%
Trial phase	Phase 2	Phase 3

Important: These results are from different trial phases and populations; direct comparison has limitations.

Body Composition

Measure	Pemvidutide	Tirzepatide
Fat mass loss	Emphasized	Primary outcome
Lean mass preservation	Claimed advantage	Standard for class
Body composition data	Limited	Some available

Pemvidutide’s claim: Glucagon agonism may help preserve lean mass during weight loss by increasing energy expenditure rather than purely reducing intake. This requires validation in larger trials.

Evidence Strength Comparison

Factor	Pemvidutide	Tirzepatide
Peer-reviewed studies	Limited	Extensive
Phase 3 trials	None	Multiple completed
Total patients studied	Hundreds	Thousands
Long-term safety	Unknown	Established
Overall quality	Low (Phase 2)	High

NASH/MASH Potential

Pemvidutide for Liver Disease

Factor	Status
Mechanism rationale	Glucagon promotes hepatic fat oxidation
Clinical data	Phase 2 ongoing
Liver enzyme effects	Improvements observed
Histologic outcomes	Pending

Tirzepatide for Liver Disease

Factor	Status
Mechanism	Indirect via weight loss
SYNERGY-NASH trial	Phase 3 ongoing
Early liver data	Encouraging
Approval status	Not yet approved for NASH

Side Effects

Pemvidutide (Phase 2 Data)

Side Effect	Incidence	Notes
Nausea	Common	GLP-1 class effect
Vomiting	Common	Expected
Diarrhea	Moderate	—
Hyperglycemia risk	Theoretical	Glucagon effect counterbalanced
Heart rate increase	Observed	Monitoring required

Tirzepatide (Established)

Side Effect	Incidence	Notes
Nausea	12-33%	Dose-dependent
Diarrhea	12-21%	Usually transient
Vomiting	5-12%	Improves with titration
Constipation	6-12%	Common

Theoretical Concerns

Pemvidutide:

• Glucagon agonism could theoretically raise blood glucose
• Current data suggests GLP-1 component compensates
• Long-term cardiovascular effects unknown
• Heart rate increases warrant monitoring

Tirzepatide:

• Well-characterized GI tolerability
• Rare pancreatitis risk
• Thyroid C-cell warnings (precautionary)

Regulatory Status

Aspect	Pemvidutide	Tirzepatide
FDA (T2D)	Not pursued	Approved (Mounjaro)
FDA (Obesity)	Not approved	Approved (Zepbound)
FDA (NASH)	Not approved	Not approved
Development stage	Phase 2	Phase 3/Post-marketing
Availability	Clinical trials	Prescription

Differentiation Strategy

Why Glucagon Agonism?

Altimmune’s rationale for including glucagon:

1. Increases energy expenditure (thermogenesis)
2. May preserve lean mass during weight loss
3. Direct hepatic lipid oxidation for NASH
4. Potentially different patient response profile

Tirzepatide’s GIP Advantage

Lilly’s rationale for GIP agonism:

1. Enhances GLP-1 effects
2. Well-tolerated combination
3. Proven efficacy in large trials
4. Favorable glucose control

Who Might Consider Each

Tirzepatide (Available Now):

• Type 2 diabetes patients
• Chronic weight management with BMI criteria
• Those wanting proven, approved therapy
• Standard first-line consideration

Pemvidutide (If Approved):

• Must await clinical trial completion
• May be positioned for NASH/MASH
• Patients interested in body composition benefits
• Those who haven’t responded to other agents

Summary

Factor	Pemvidutide	Tirzepatide
Evidence quality	Low (Phase 2)	High (approved)
Weight loss	~15.6% (48 wks)	~22% (72 wks)
Mechanism	GLP-1/Glucagon	GLP-1/GIP
NASH potential	Central focus	Also in development
Availability	Clinical trials	Prescription
Lean mass preservation	Claimed advantage	Standard

Key takeaway: These represent different dual agonist strategies. Tirzepatide is approved with robust data. Pemvidutide’s glucagon-based approach shows promise, particularly for NASH, but requires Phase 3 validation. The question of which dual combination is optimal remains under investigation.

---

This comparison is for educational purposes only. Pemvidutide is not FDA-approved. Tirzepatide requires a prescription. Consult a healthcare provider for treatment decisions.